5 Key Takeaways

• 1

  Combination therapy with reduced-fluence photodynamic therapy and aflibercept did not improve visual acuity compared to aflibercept alone.

• 2

  The study showed higher early polypoidal lesion closure rates with combination therapy at week 12 compared to monotherapy.

• 3

  At week 52, lesion closure rates were 73% for combination therapy versus 47% for monotherapy.

• 4

  No serious adverse events were reported in either treatment group during the trial.

• 5

  The study faced limitations due to a smaller sample size and delays, impacting the ability to draw definitive conclusions.